Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell ALK-/CD30+ lymphoma occurring in 7—10 years after implantation of breast prostheses (textured forms as a rule). BIA-ALCL incidence ranges from 1:1000 to 1:10 000. To date, over 500 cases of BIA-ALCL are confirmed among 35 million implantations in the world. BIA-ALCL requires only surgical treatment after early diagnosis. Adherence to the modern guidelines on the diagnosis and treatment of this disease ensures complete recovery in most patients with BIA-ALCL. Nevertheless, adjuvant therapy including radio- and chemotherapy with brentuximab vedotin is required for tumor stage II—IV. Increased awareness of physicians and patients about the risks of BIA-ALCL, as well as targeted collection of epidemiological data can result an increased number of newly detected cases in the Russian Federation.

Keywords. breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), anaplastic large cell lymphomas (ALCL), Food and Drug Administration, anaplastic lymphoma kinase